Compare Altria Group Inc (MO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Zoetis Inc — how do they compare? Altria Group Inc trades at $73.24 (market cap $124.67B), while Zoetis Inc trades at $75.47 (market cap $31.95B). The key difference: Altria Group Inc is far larger — about 3.9× Zoetis Inc's market cap, and Altria Group Inc pays the higher dividend (5.68%). Which is the better fit depends on your goals.
| MO | ZTS | |
|---|---|---|
Market Cap | $124.67B | $31.95B |
Sector | Consumer Staples | Health |
52-Week High | $74.66 | $156.76 |
52-Week Low | $54.72 | $71.91 |
Enterprise Value | $145.75B | $39.24B |
Dividend Yield | 5.68% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $72.99, down 1.64% on the day, with a P/E of 15.59 and strong net income margin of 39.52%. Recent earnings show mixed results, beating estimates in Q1 2026 but missing in Q4 2025. Technical indicators suggest a bullish trend with support at $73 and resistance at $75. The company maintains robust cash flow from operations at $9.29B and declared a $1.06 dividend payable in July 2026.
MO offers a high dividend yield and stable cash flows, appealing for income investors, but faces risks from declining smoking trends and regulatory pressures. Analyst consensus is bullish with a $71 price target, though revenue stagnation and debt levels warrant caution. The stock's defensive qualities provide stability amid market volatility.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
